Pitié-Salpêtrière University Hospital is a teaching hospital in the 13th arrondissement of Paris. Part of the Assistance Publique – Hôpitaux de Paris and a teaching hospital of Sorbonne University, it is one of Europe's largest hospitals. It is also France's largest hospital.

During the past decade, Hôpital Pitié Salpêtrière conducted 762 clinical trials. In the 10-year time frame, 762 clinical trials started and 120 clinical trials were completed, i.e. on average, 15.7% percent of trials that started reached the finish line to date. In the past 5 years, 393 clinical trials started and 83 clinical trials were completed. i.e. 21.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Pitié Salpêtrière" #1 sponsor was "Assistance Publique - Hôpitaux de Paris" with 245 trials, followed by "Institut National de la Santé Et de la Recherche Médicale, France" with 29 trials sponsored, "Nantes University Hospital" with 28 trials sponsored, "UNICANCER" with 24 trials sponsored and "European Organisation for Research and Treatment of Cancer - EORTC" with 24 trials sponsored. Other sponsors include 847 different institutions and companies that sponsored additional 353 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Pitié Salpêtrière" #1 collaborator was "Ministry of Health, France" with 35 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 17 trials as a collaborator, "Institut National de la Santé Et de la Recherche Médicale, France" with 17 trials as a collaborator, "Groupe Hospitalier Pitie-Salpetriere" with 13 trials as a collaborator and "Hoffmann-La Roche" with 9 trials as a collaborator. Other collaborators include 719 different institutions and companies that were collaborators in the rest 525 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Pitié Salpêtrière" are "Amyotrophic Lateral Sclerosis" (25 trials), "Multiple Sclerosis" (19 trials), "Parkinson's Disease" (18 trials), "Breast Cancer" (17 trials) and "Parkinson Disease" (17 trials). Many other conditions were trialed in "Hôpital Pitié Salpêtrière" in a lesser frequency.

Most popular intervention types in "Hôpital Pitié Salpêtrière" are "Drug" (589 trials), "Other" (216 trials), "Device" (161 trials), "Procedure" (113 trials) and "Biological" (59 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (114 trials), "placebo" (19 trials), "Gemcitabine" (17 trials), "Rituximab" (14 trials) and "radiation therapy" (14 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Pitié Salpêtrière" are 1117 trials for "All" genders, 50 trials for "Female" genders and 33 trials for "Male" genders.

Currently, there are 390 active trials in "Hôpital Pitié Salpêtrière". 36 are not yet recruiting, 251 are recruiting, 101 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 558 completed trials in Hôpital Pitié Salpêtrière, 3 suspended trials, and 111 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Pitié Salpêtrière, 49 "Phase 1" clinical trials were conducted, 281 "Phase 2" clinical trials and 318 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 49 trials, and there were also 279 trials that are defined as “Not Applicable".